Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
This study is testing a specialized cellular therapy called brexucabtagene autoleucel to see how safe it is and how well it helps control a fast-growing blood cancer called B-cell acute lymphocytic leukemia. Researchers want to see if giving this treatment after standard chemotherapy and immunotherapy can help patients stay cancer-free.
Adults aged 18 and older who have B-cell acute lymphocytic leukemia that has either come back, did not respond to past treatments, or is newly diagnosed with high-risk genetic features may be able to join. However, patients with a specific genetic mutation called the Philadelphia chromosome or those who have had similar cell therapies before cannot participate.
Participants will first receive specific combinations of chemotherapy and immunotherapy to help lower the amount of cancer in their bodies. Following this preparation, they will receive the study treatment, brexucabtagene autoleucel, and be closely monitored by the medical team for safety and effectiveness.
This study is currently active and recruiting participants in Houston, Texas, United States.
- 1Tests a specialized immune-based cell therapy for a type of blood and bone marrow cancer.
- 2Combines standard chemotherapy medicines with the study treatment to target leukemia cells.
- 3Currently recruiting participants at a location in Houston, Texas.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.